The upgrade in price target by a reputable analyst like Leland Gershell from Oppenheimer is a strong positive signal for Protara Therapeutics. It suggests confidence in the company's future performance and potential for stock price appreciation. Such endorsements often lead to increased investor interest and can drive the stock price up in the short term.